See more : TASCO Bhd (5140.KL) Income Statement Analysis – Financial Results
Complete financial analysis of 3D Global Biotech Inc. (6808.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 3D Global Biotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Omni-Plus System Limited (7699.T) Income Statement Analysis – Financial Results
- Biovica International AB (publ) (BIOVIC-B.ST) Income Statement Analysis – Financial Results
- DigiAsia Corp. (FAAS) Income Statement Analysis – Financial Results
- Heng Tai Consumables Group Limited (0197.HK) Income Statement Analysis – Financial Results
- PT BFI Finance Indonesia Tbk (BFIN.JK) Income Statement Analysis – Financial Results
3D Global Biotech Inc. (6808.TWO)
About 3D Global Biotech Inc.
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 20.63M | 13.64M | 11.08M | 13.26M | 18.18M |
| Cost of Revenue | 15.36M | 10.93M | 9.27M | 8.29M | 10.25M |
| Gross Profit | 5.27M | 2.72M | 1.80M | 4.97M | 7.92M |
| Gross Profit Ratio | 25.56% | 19.91% | 16.28% | 37.49% | 43.59% |
| Research & Development | 38.60M | 39.48M | 37.60M | 35.62M | 0.00 |
| General & Administrative | 11.01M | 11.23M | 11.81M | 11.16M | 0.00 |
| Selling & Marketing | 18.52M | 18.29M | 14.60M | 8.52M | 0.00 |
| SG&A | 29.53M | 29.53M | 26.41M | 19.68M | 29.71M |
| Other Expenses | 0.00 | -18.27M | 155.00K | 241.00K | 0.00 |
| Operating Expenses | 5.27M | 69.00M | 64.01M | 55.30M | 41.63M |
| Cost & Expenses | 83.49M | 79.93M | 73.28M | 63.59M | 51.88M |
| Interest Income | 2.24M | 1.68M | 1.35M | 1.71M | 1.42M |
| Interest Expense | 176.00K | 255.00K | 261.00K | 101.00K | 49.00K |
| Depreciation & Amortization | 22.89M | 25.86M | 24.89M | 24.34M | 11.28M |
| EBITDA | -35.85M | -57.02M | -35.82M | -24.04M | -18.15M |
| EBITDA Ratio | -173.73% | -417.91% | -323.42% | -181.25% | -137.65% |
| Operating Income | -62.85M | -82.88M | -60.71M | -48.38M | -36.31M |
| Operating Income Ratio | -304.62% | -607.48% | -548.14% | -364.81% | -199.73% |
| Total Other Income/Expenses | 3.94M | -16.85M | 1.24M | 1.85M | 2.55M |
| Income Before Tax | -58.92M | -83.13M | -60.97M | -48.48M | -33.75M |
| Income Before Tax Ratio | -285.54% | -609.35% | -550.49% | -365.57% | -185.69% |
| Income Tax Expense | -964.00K | -16.05M | -1.26M | -560.00K | 2.56M |
| Net Income | -57.95M | -67.09M | -59.71M | -47.92M | -36.32M |
| Net Income Ratio | -280.87% | -491.72% | -539.10% | -361.35% | -199.79% |
| EPS | -1.03 | -1.22 | -1.11 | -0.89 | -0.72 |
| EPS Diluted | -1.03 | -1.22 | -1.11 | -0.89 | -0.72 |
| Weighted Avg Shares Out | 56.15M | 54.88M | 53.97M | 53.56M | 50.52M |
| Weighted Avg Shares Out (Dil) | 56.15M | 54.88M | 53.97M | 53.56M | 50.52M |
Source: https://incomestatements.info
Category: Stock Reports